Imugene Limited (IMU.AX)
| Previous close | 0.3600 |
| Open | 0.3650 |
| Bid | 0.3600 x 102397000 |
| Ask | 0.3650 x 716752400 |
| Day's range | 0.3550 - 0.3670 |
| 52-week range | 0.0920 - 0.6250 |
| Volume | |
| Avg. volume | 24,428,959 |
| Market cap | 2.089B |
| Beta (5Y monthly) | 1.94 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0040 |
| Earnings date | 23 Feb 2022 - 27 Feb 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 0.58 |
- GlobeNewswire
Imugene Announces Clinical Trial Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate HER-Vaxx in Combination with Avelumab for Treatment of Gastric Cancer
New clinical trial supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer Inc.Avelumab (BAVENCIO®) to be provided to Imugene for Phase 2 clinical study in HER-2 positive gastric or gastroesophageal junction adenocarcinomas (neoHERIZON)neoHERIZON will assess HER-Vaxx in combination with chemotherapy with or without avelumab in HER-2 positive gastric cancer SYDNEY, Australia., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Imugene (ASX: IMU) today announced a new clinical trial supply agreement with M
- Business Wire
Imugene and Eureka Therapeutics Announce Strategic Collaboration to Accelerate Advancement of Oncolytic Virus and T-Cell Therapy in Solid Tumours
SYDNEY & EMERYVILLE, Calif., November 01, 2021--Imugene Ltd ("Imugene") (ASX: IMU), a clinical stage immuno-oncology company, and Eureka Therapeutics, Inc. ("Eureka"), a clinical-stage biotechnology company developing novel T-cell therapies to treat solid tumours, today announced a strategic collaboration to evaluate Imugene’s CD19 oncolytic virus onCARlytics technology in combination with Eureka’s anti-CD19 ARTEMIS® T-cell therapy for the treatment of solid tumours.
- GlobeNewswire
Imugene and Celularity Announce an Exclusive Strategic Partnership to Develop a Novel Oncolytic Virus - Allogeneic CAR T-Cell Immunotherapy Combination for the Treatment of Solid Tumors
Collaboration will initially explore the therapeutic potential of a combination of Imugene’s CF33-CD19 oncolytic virus (onCARlytics) and Celularity’s CD19 targeting chimeric antigen receptor (CAR) placental-derived investigational T-cell therapy, CyCART-19Nonclinical in vitro and in vivo combination studies to commence in 2021Celularity’s off-the-shelf allogeneic CD19 therapy has shown sustained T-cell growth with continuous killing of tumor cells in vivo1Combining Imugene’s oncolytic virus tech
